~~<i id='81362D003D'><strike id='81362D003D'><tt id='81362D003D'><pre id='81362D003D'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：leisure time 2025-09-29 03:07:27 Page View：9573

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： NYU radiologists take on the challenge of expensive MRI machines
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts

explore

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

KenaBetancur/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbi

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

NovoNordiskviaAPPHILADELPHIA—NovoNordisk’sobesitydrugWegovynotablycuttheriskofheartattacksinalandmar